DEERFIELD, Ill.--(BUSINESS WIRE)--Dade Behring Inc. (NASDAQ:DADE), the world’s largest company solely dedicated to clinical diagnostics, announced today that it has granted certain rights to Beckman Coulter for the combined use of the emerging cardiac markers placental growth factor (PIGF), soluble fms-like tyrosine kinase 1(sFlt-1), soluble CD40 ligand (sCD40L) and pregnancy associated plasma protein-A (PAPP-A). In addition, Beckman Coulter has granted certain cardiac-related rights to Dade Behring for the use of PAPP-A. Studies show all of these cardiac markers to have potential to be useful in the diagnosis and prognosis of cardiovascular disease1-3, which remains the leading cause of death worldwide.
